Avilamycin did not play a role in the discontinuation of evernimicin as a clinical drug candidate.
Belanger
Aimee E
AE
Shryock
Thomas R
TR
D000617:Aminoglycosides / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D024881:Drug Resistance, Bacterial; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008968:Molecular Conformation; D015394:Molecular Structure; D009844:Oligosaccharides / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use
D000617:Aminoglycosides; D009844:Oligosaccharides; C001202:evernimicin; C006653:avilamycin